MRI-guided Focused Ultrasound Therapy Market is expected to reach US$ 1,027.63 Million by 2034

Breast Cancer Segment Drives MRI-guided Focused Ultrasound Therapy Market Growth

According to our new research study named "MRI-guided Focused Ultrasound Therapy Market Forecast to 2034 – Global Analysis – by Application, End User, and Geography," the market was valued at US$ 441.73 million in 2025 and is projected to reach US$ 1,027.63 million by 2034; it is expected to register a CAGR of 10.0% during 2026–2034. The rising prevalence of targeted diseases, technological advancements and regulatory approvals, and the shift towards noninvasive therapies and an aging population, drive the adoption of MRI-guided focused ultrasound therapy. Development of portable and hybrid systems, enhanced imaging and real-time thermometry are projected to drive MRI-guided focused ultrasound therapy market trends in the coming years.

MRI-guided focused ultrasound therapy advances medicine through its noninvasive method, which uses high-intensity ultrasound beams that medical professionals guide with real-time MRI technology to achieve precise tissue destruction. The technique provides treatment for tumors and uterine fibroids and neurological disorders, and chronic pain through its noninvasive approach, which avoids both surgical incisions and radiation exposure. Rising demand for noninvasive treatments, increasing prevalence of cancer, neurological disorders, and uterine fibroids, and growing geriatric populations are driving global MRI-guided focused ultrasound therapy market growth. Additionally, technological advances in MRI imaging, ultrasound precision, and real-time monitoring improve safety and outcomes, driving growth in the MRI-guided focused ultrasound therapy market size. Reduced hospital stays, faster recovery, lower complication rates, and expanding clinical indications encourage adoption. Supportive regulatory approvals, growing healthcare investments, and patient preference for incision-free therapies accelerate market growth worldwide across emerging and developed healthcare systems, contributing to the rising MRI-guided focused ultrasound therapy market size. 

MRI-guided Focused Ultrasound Therapy Market, by Region, 2025 (%)

Source: The Insight Partners Analysis

MRI-guided Focused Ultrasound Therapy Market Analysis Based on Segmental Evaluation:

Based on application, the MRI-guided focused ultrasound therapy market is segmented into breast cancer, prostate cancer, liver cancer, pancreatic cancer, breast lifting and aesthetic application, nipple and areola preservation, post-surgical applications, and others. The breast cancer segment held a significant MRI-guided focused ultrasound therapy market share in 2025. The segment experiences growth as breast cancer cases worldwide are increasing, and people require minimally invasive treatment methods. The noninvasive treatments, which allow patients to experience less pain and reduced scarring while spending less time in hospitals, also provide them with faster recovery results than surgical procedures. The development of better imaging systems and thermal monitoring tools has enabled doctors to perform safer breast tumor surgeries with more accurate treatment outcomes. Better screening programs, which detect diseases at earlier stages, have been developed. The segment observes increased adoption as people understand focused ultrasound better, and research shows positive clinical outcomes, which prove its effectiveness as both a main treatment and supplementary therapy.

The geographical scope of the MRI-guided focused ultrasound therapy market report encompasses an assessment of the market performance in North America, Europe, Asia Pacific, South America, Central America, the Middle East, and Africa. North America dominated the MRI-guided focused ultrasound therapy market share in 2025. The region's advanced medical systems and high per capita healthcare spending support the widespread adoption of cutting-edge therapies such as MR-guided focused ultrasound, especially in oncology and neurology applications where precise, noninvasive treatments are preferred by providers and patients alike. The US benefits from early FDA approvals for key indications and a large network of academic research centers that generate clinical evidence and accelerate commercialization, thereby boosting MRI-guided focused ultrasound therapy market growth. North America has established reimbursement systems that help hospitals and patients pay for nonsurgical treatments that are part of value-based care systems. The continuous use of artificial intelligence and advanced MRI imaging technology creates better treatment planning solutions that healthcare systems, which prioritize innovation and efficiency, can improve their operational performance through these advancements.

The University of Maryland Medical System will lead a clinical trial in November 2025, which demonstrates that glioblastoma patients experience ~40% increased survival when MRgFUS creates blood-brain barrier openings to improve chemotherapy delivery, resulting in a median overall survival that exceeds 30 months, while control patients survive only 19 months. The MDS Congress in October 2025 showcased phase 3 trial results, which proved that staged bilateral MRgFUS pallidothalamic tractotomy delivered substantial motor symptom relief to Parkinson's patients who experienced treatment difficulties, which resulted in FDA approval for Insightec's Exablate Neuro platform to perform bilateral procedures. The MRgFUS system for essential tremor and Parkinson's tremor treatment has been expanded by Northwestern Medicine since June 2025, which provides immediate noninvasive advantages to patients. These advancements underscore MRgFUS's growing role in precise, outpatient care, with ongoing trials exploring its applications in brain tumors and Alzheimer's disease, which supports the continuous growth of the MRI-guided focused ultrasound therapy market in North America.

Moreover, the development of focused ultrasound therapy shows increasing adoption through key milestones and technological breakthroughs, which enable more private hospitals to receive MRgFUS systems. Chongqing Haifu Medical Technology introduced its Focused Ultrasound Tumor Therapeutic Systems to Mexico, bringing China?developed HIFU ablation technology to local medical centers. The company launched its advanced FUS systems in Mexico in December 2020, and the country became one of Latin America's earliest adopters of Haifu equipment by early 2022. Hence, the above-mentioned factors collectively support the growth of the global MRI-guided focused ultrasound therapy market.Edap Tms SA, Insightec Ltd., Koninklijke Philips NV, FUS Instruments Inc., Image Guided Therapy SA, Profound Medical Corp., Arrayus Technologies Inc., EpiSonica, NaviFUS Corp., and Changjiangyuan Technology Development Co. Ltd. are among the leading companies profiled in the MRI-guided focused ultrasound therapy market report. 

Based on application, the MRI-guided focused ultrasound therapy market is segmented into breast cancer, prostate cancer, liver cancer, pancreatic cancer, breast lifting and aesthetic application, nipple and areola preservation, post-surgical applications, and other applications. By end user, the market is classified into healthcare facilities, diagnostic imaging centers, and research centers. Geographically, the MRI-guided focused ultrasound therapy market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).
 

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com